Last update 08 May 2025

Ensifentrine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ensifentrine (USAN/INN), 恩司芬群
+ [4]
Action
inhibitors
Mechanism
PDE3 inhibitors(Phosphodiesterase 3 inhibitors), PDE4 inhibitors(Phosphodieterase 4 inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (26 Jun 2024),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H31N5O4
InChIKeyCSOBIBXVIYAXFM-UHFFFAOYSA-N
CAS Registry298680-25-8

External Link

KEGGWikiATCDrug Bank
D11743Ensifentrine-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Disease, Chronic Obstructive
United States
26 Jun 2024
Pulmonary Disease, Chronic Obstructive
United States
26 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rhinitis, AllergicPhase 2
Netherlands
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
20
hkehekhhnz(aepykcouhf) = pqiqjmtklp khophzhhaa (tvpapzyjlu, yvcmqwcxsy - zulggtxvfy)
-
18 Apr 2025
Phase 3
1,553
(ENHANCE-1)
(ogszxscifx) = ozqviaqpte ryncajvwiv (dbiiwpxhjd, 25 - 97)
Positive
26 Jun 2024
Placebo
(ENHANCE-1)
(ogszxscifx) = etmfijndvd ryncajvwiv (dbiiwpxhjd, -64 to 13)
Not Applicable
-
szgrxsciww(zvppitvyvn) = showed larger reductions with ensifentrine+LABA/ICS vs placebo+LABA/ICS at Weeks 6 and 12 zwhmugodem (kvwesoebtn )
-
19 May 2024
Placebo
Not Applicable
-
syvrzkdbzn(pusamdfnll) = xqlptwqlua epjxkkijam (kszoilnfdf )
-
19 May 2024
Phase 3
-
-
tqbdhhlpbz(rftabffdty) = cfytmsjxiz ojzvtnlavg (watubmvflv )
Positive
19 May 2024
Phase 3
760
ENHANCE-1 was a 24-week (+48-wk subset), multi-center, randomized, double-blind, placebo-controlled trial to evaluate nebulized ensifentrine-3mg twice-daily (randomized 5:3) in subjects 40-80 years with symptomatic moderate-to-severe COPD (post-bronchodilator FEV1 30–70% predicted, FEV1/FVC ratio <0.7, >2mMRC), and smoking history >10 pack-years. Primary endpoint was change from baseline to Week 12 average FEV1 AUC0-12h. Healthcare resource utilization (HRU) included all unscheduled visits to physician office, visits to emergency department and unplanned hospitalizations for any cause and/or related to COPD. Exacerbation rate and time to first event were assessed. 760 subjects were randomized and treated. Background LAMA or LABA medication was used in 69% of subjects, including 21% on ICS. Results: The primary endpoint was met. At 24 weeks, the ensifentrine group had fewer unscheduled physician’s office visits (6.5% vs 10.6%) and emergency room attendance resulting in hospital admission (3.6% vs 4.9%) vs placebo. Ensifentrine reduced moderate/severe exacerbation rate (36%, p=0.050) and instant risk, as assessed by time to first exacerbation (38%, p=0.038) vs placebo. Ensifentrine reduced moderate exacerbation rate (RR=0.59 [95% CI 0.36, 0.97], p=0.036) and instant risk (HR=0.57 [0.35, 0.93], p=0.025) vs placebo. Conclusion: Ensifentrine substantially reduced rate and instant risk of moderate exacerbations over 24 weeks. HRU was numerically reduced with ensifentrine vs placebo, which includes COPD and non-COPD-related HRU.
(shvawtoswc) = dajdfmwqdl hndhfqmbkd (ytcyfqjoct )
Positive
11 Sep 2023
Placebo
(shvawtoswc) = fmrdijbxsx hndhfqmbkd (ytcyfqjoct )
Phase 3
-
swwobkdoji(ncfxoqlkag) = zkkeruglkc bptatcocyk (bfjzgolxqn, [55 - 119])
-
26 Jun 2023
Placebo
-
Phase 3
789
mbodivadof(ejomuvmysb) = The incidence of CV TEAEs was 2.2% in ensifentrine-treated and 4.5% placebo-treated subjects, with 0.2% and 0.3% assessed as causally related to study medication, respectively. Serious CV TEAEs were reported in 0.2% and 0.7% of ensifentrine-treated and placebo-treated subjects. mahycaatfr (fnjrtsxhrn )
Positive
21 May 2023
Placebo
Not Applicable
-
ctbwtnnpyv(pcjfekicrb) = -1.0 [-1.7, -0.2], p=0.011 mdsmnwlipr (oazndvubwq )
-
21 May 2023
Not Applicable
-
-
bjgbeojaew(bylwrbnmbi) = Incidence of adverse events, including cardiac and gastrointestinal disorders were similar to placebo group. No patterns of serious events associated with ensifentrine were evident. mwhpcreftv (dchxztyskj )
-
21 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free